Global law firm White & Case LLP has advised Morgan Stanley, Goldman Sachs, Jefferies and Unicredit as mandated lead arrangers on the debt financing for Zentiva's acquisition of Alvogen's business in Central & Eastern Europe (CEE).
"The deal adds to our long track record of advising leading banks as they act on significant cross-border transactions across EMEA," said White & Case partner Ben Wilkinson, who led the Firm's deal team.
The terms of the acquisition have not been disclosed. The divested CEE platform includes more than 200 generic and over-the-counter (OTC) products across multiple therapeutic areas which cover 14 key regional markets.
Alvogen is a global, privately-owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, OTC medicines and biosimilar products for patients around the world. It has commercial operations across Asia-Pacific and the US and R&D centers in the US, South Korea, and Taiwan.
Zentiva employs more than 3,000 people and produces affordable medicines serving patients in Europe and beyond from a network of production sites, including flagship sites in Prague and Bucharest.
The White & Case team in London which advised on the transaction was led by partner Ben Wilkinson and included associates Sylvana Lee and Rizwan Latif.
For more information please speak to your local media contact.